Global Breast Cancer Screening Market, By Test Type; By End User-Estimation & Forecast, 2017-2030

Global Breast Cancer Screening Market: Poised to Reach US$ 15.01 Bn by 2030

With an estimated value of US$ 7.46 Bn in 2022, the global Breast Cancer Screening market is expected to experience a substantial surge over the next eight years, reaching a market size of US$ 15.01 Bn by 2030. The market is expected to grow at a CAGR of 9.49% due to increasing breast cancer prevalence and a growing geriatric population.

Growth Influencers:

The rising prevalence of breast cancer worldwide and an increasing geriatric population are significant drivers of the Breast Cancer Screening market. However, the market's growth is hampered by the high costs of screening tests and uncertainties surrounding reimbursement policies related to breast cancer molecular diagnostics.

Segments Overview:

The market is segmented by test type and end user.

By Test Type

• Imaging Tests
• Ultrasound
• MRI
• Mammogram
• Film mammography
• Digital mammography

Digital breast tomosynthesis (DBT)

• Genetic Tests
• Other screening Tests

By End User

• Research Labs
• Cancer Institutes
• Diagnostics Centers
• Others

Imaging tests are forecasted to exceed US$ 9000 Mn by 2030 in terms of revenue. Diagnostic centers hold more than 30% of the market share in 2022, while the 'Others' segment, including private clinics and hospitals, is expected to witness the highest CAGR of more than 9%.

Regional Overview:

On the bases of region, the market is segmented into North America, Europe, Asia Pacific, South America, Middle East & Africa.

North America

• US
• Canada
• Mexico

Europe

• Western Europe
• UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Russia
• Poland
• Rest of Eastern Europe

Asia Pacific

• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Singapore
• Rest of ASEAN
• Rest of Asia Pacific

Middle East & Africa

• UAE
• Saudi Arabia
• South Africa
• Rest of MEA

South America

• Brazil
• Argentina
• Rest of South America

Regionally, North America dominates the market, holding more than 30% of the market share in 2022 with revenue of US$ 2355.9 Mn. The region's dominance is attributed to advanced healthcare infrastructure, rising awareness about early detection, and favorable reimbursement policies.

Competitive Landscape:

The market is characterized by competition among key players such as Siemens Healthcare, Hologic, Inc., Myriad Genetics, Metabolomic Technologies Inc., Biocrates Lifesciences AG, A&G Pharmaceuticals, Provista Diagnostics Inc., Roche Diagnostics, Lineage Cell Therapeutics, Inc. (Biotime Inc.), General Electric Company, Quest Diagnostics, Agendia NV, Oncocyte Corporation, Allengers Medical Systems Ltd., and others, collectively accounting for a market share close to 35%.

Report Insight:

• Detailed analysis of market segments
• Comprehensive understanding of growth influencers
• In-depth regional market overview
• Profound insights into the competitive landscape
• Future market growth predictions

Questions to be Answered in the Report:

• What are the key trends and opportunities in the Breast Cancer Screening market?
• What will be the market size and growth rate by 2030?
• Who are the major players in the Breast Cancer Screening market?
• What are the key drivers and restraints of the market?
• What are the emerging trends in breast cancer screening?